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Abstract
Background: In this study, we report our experience of cytoreductive surgery plus hyperthermic intraperitoneal
chemotherapy (CRS-HIPEC) in patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC), focusing on
the factors affecting survival.
Methods: All patients with surgically treated PC from colorectal cancer and with no involvement of other organs
referred to our institute from March 2005 to December 2017 were included in the analysis.
Results: Thirty-eight patients underwent CRS-HIPEC, and all had a completeness of cytoreduction score of 0 (CC0).
The median operating time was 645 min (interquartile range [IQR] 565–710). Five patients (13.1%) had Clavien-
Dindo grade > 2 postoperative complications. Median overall survival (OS) was 60 months. In the Cox regression for
OS, calculated on the CRS-HIPEC group, the peritoneal cancer index (PCI) > 6 (hazard ratio [HR] 4.48, IQR 1.68–11.9,
P = 0.003) and significant nodal involvement (N2) (HR 3.89, IQR 1.50–10.1, P = 0.005) were independent prognostic
factors. Median disease-free survival (DFS) was 16 months. Only N2 (HR 2.44, IQR 1.11–5.36, P = 0.027) was a
significantly negative prognostic factor for DFS in multivariate analysis.
Conclusions: CRS-HIPEC can substantially improve survival. However, patients with high PCI (PCI > 6) and
significant nodal involvement (N2) may not benefit from the procedure.
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Introduction
The peritoneum is the second most common site of me-
tastasis in colorectal cancer (CRC), with a incidence of
25–35% [1, 2]. Peritoneal carcinomatosis (PC) confers a
poorer prognosis than other metastatic sites [3, 4]. It has
been seen that patients with PC undergoing modern sys-
temic chemotherapy show a median survival of at least 22
months [3]. Cytoreduction plus hyperthermic intraperito-
neal chemotherapy (CRS-HIPEC) [5, 6] represents a fur-
ther treatment option for patients with PC from CRC,
obtaining median survival rates of around 60 months [7–
10]. However, studies on CRS-HIPEC are characterized by
limited sample sizes, heterogeneous patients, and lack of
control groups, resulting in guidelines containing weak
recommendations based on low-quality evidence [11].
In the present study, we analyze our experience of
CRS-HIPEC in patients with PC from CRC, focusing on
the factors influencing survival.
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Material and methods
Patients with surgically treated PC from CRC without in-
volvement of other organs referred to our institute from
March 2005 to December 2017 were included in this ana-
lysis. Exclusion criteria were age > 75 years, American Soci-
ety of Anesthesiologists (ASA) score > 2, and technically
unresectable tumor (massive involvement of hepatic hilum
or full-thickness involvement of the diaphragm). The work
was reported in line with the Strengthening the Reporting of
Cohort Studies in Surgery (STROCSS) criteria [12].
Definitions and treatment protocol
The primary outcome measure was OS which was de-
fined as the time between surgery and last follow-up or
death. DFS was defined as shown elsewhere [13]. The
definitions of peritoneal cancer index (PCI) and com-
pleteness of cytoreduction (CC) score are defined in de-
tail elsewhere [14]. CC0 defines no residual peritoneal
lesions within the operative field, CC1 refers to persist-
ing nodules < 2.5 cm after CRS, CC2 indicates nodules
between 2.5 and 5 cm, and CC-3 refers to nodules > 5
cm or confluent unresectable tumor nodules. The 7th
edition of the AJCC Cancer Staging Manual was used to
stage the disease at histological evaluation [15].
All patients underwent CRS-HIPEC in the Department
of General and Oncologic Surgery of Morgagni-Pierantoni
Hospital, Forlì (Italy). As per protocol, HIPEC was offered
to ASA 1-2 patients > 75 years. Peritonectomies were per-
formed using the Sugarbaker technique [6]. Peritoneal
washings were performed with intravenous 5-fluorouracil
(400 mg/m2) and intraperitoneal oxaliplatin (400 mg/m2)
for 30 min at 41.5 °C.
Statistical analysis
An additional analysis was performed comparing patients
receiving CRS-HIPEC at our center (tertiary referral hos-
pital) with those who had undergone incomplete cytore-
duction (no HIPEC) elsewhere before being referred to
our oncology unit. Consequently, information regarding
operative/early postoperative outcomes and the CC score
in the latter group was not available. Median and inter-
quartile range (IQR) were used to present continuous vari-
ables which were compared using the Mann-Whitney U
test. Fisher’s exact test was performed to compare dichotom-
ous variables. The Kaplan-Meier function was exploited for
survival analyses, and differences were evaluated by the log
rank test. Cox proportional hazard regression was used to
identify independent prognostic factors among the variables
included in the analyses (age, sex, site of primitive tumor,
PCI, synchronous vs metachronous carcinomatosis, pre-post
surgery chemotherapy, synchronous vs metachronous
HIPEC, tumor grade, tumor [T], and nodal [N] status). The
cutoff for PCI used in the survival analyses was calculated
with “Cutoff Finder,” as proposed by Budczies et al. [16].
Follow-up time was calculated using the method proposed
by Schemper and Smith [17]. MedCalc (MedCalc ® for Win-
dows ® , version 10.2.0.0; MedCalc Software, Ostend,
Belgium) was used to perform the statistical analyses.
Results
Of the 38 patients included in the analysis (Table 1), 25
(65.8%) had undergone preoperative chemotherapy. Surgery
in all 38 patients was CC0. Median operating time for
CRS-HIPEC was 645 min (IQR 565–710). In the 10
(26.3%) patients treated for synchronous carcinomatosis,
resections included 2 right colectomy only, 2 plus rectal re-
section, 1 plus jejunal resection, 1 plus hysteroannessiect-
omy, 2 rectal resection only, 1 plus jejunal resection, and 1
left colectomy. Five (13.1%) patients had Clavien-Dindo
grade > 2 postoperative complications, of whom three re-
quired surgical management (one for evisceration, one for
ileal perforation, and one for ileocolic anastomosis leak).
There were no cases of in-hospital mortality. Median length
of hospital stay was 16 days (IQR 14–20).
Median OS was 60 months, and median DFS was 16
months (Fig. 1). Median follow-up was 115 months (IQR 72–
149). In Cox regression for OS, PCI > 6 (HR 4.48 IQR 1.68–
11.9, P = 0.003) and N2 (HR 3.89 IQR 1.50–10.1, P = 0.005)
were independent prognostic factors (Table 2). Kaplan-Meier
curves of differences in survival according to PCI and N status
are shown in Fig. 2a, b. The HR of N2 patients with PCI > 6
was 6.82 (IQR 2.23–20.9, P = 0.0008) (Fig. 2c). Only N2 (HR
2.44 IQR 1.11–5.36, P = 0.027) was a significantly negative
prognostic factor for DFS in multivariate analysis (Table 2)
(Fig. 3). Twenty-seven (71%) patients relapsed during
follow-up, 16 with multiple sites of recurrence. Twenty-two
(81.5%) had peritoneal recurrence and 2 of these underwent a
second CRS-HIPEC.
CRS-HIPEC vs incomplete cytoreduction
An additional analysis was performed comparing pa-
tients submitted to CRS-HIPEC at our center (tertiary
Table 1 Patients’ characteristics
Variables
Age, years—median (IQR) 61 (53–70)
Female, n (%) 20 (52.6)
Site of the primary tumor
Rectum 5 (13.2)
Right colon 14 (36.8)
Transverse and sigmoid colon 19 (50.0)
Grade ≥ 3, n (%) 16 (42.1)
T3–T4, n (%) 37 (97.4)
N+, n (%) 25 (65.8)
Synchronous carcinomatosis, n (%) 14 (36.8)
Peritoneal cancer index—median (IQR) 5 (2–9)
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referral hospital) (n = 38) with those who had undergone
incomplete cytoreduction and no HIPEC before being
referred to our oncology unit (n = 25). The CRS-HIPEC
group was comparable with the incomplete CRS group in
terms of age (median 61 years, IQR 53–70 vs 66 years,
IQR 58–68, respectively; P = 382), rate of female patients
(20 [52.6%] vs 14 [56%]; P = 0.803), right colon cancer (14
[36.8%] vs 11 [44%]; P = 0.607), tumor grade ≥ 3 (16,
42.1% vs 11, 44%; P = 1.000), N+ tumors (25 [65.8%] vs 16
[64%]; P = 1.000), synchronous carcinomatosis (14 [36.8%]
vs 11 [44%]; P = 0.607), and median PCI (5 [IQR 2–9] vs 6
[IQR 4–12]; 0.078). The number of patients with T3–T4
CRC was significantly higher in the CRS-HIPEC group (37
[97.4%] vs 20 [80%]; P = 0.032). The median number of
lymph nodes harvested was 24 (IQR 15–35) in the
CRS-HIPEC group compared to 32 (IQR 23–39) in the in-
complete CRS group (P = 0.097). Postoperative chemother-
apy was performed in 32 (84.2%) CRS-HIPEC patients
Fig. 1 Kaplan-Meier curves showing the disease-free survival of the CRS-HIPEC group
Table 2 Cox regression analysis on overall survival and disease-free survival on CC0 patients
Variables OS DFS
Univariate Multivariate Univariate Multivariate
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age 1.01 (0.96–1.05) 0.737 1.00 (0.97–1.04) 0.705
Sex (F) 0.77 (0.31–1.83) 0.764 1.20 (0.56–2.56) 0.638
Right colon cancer 2.51 (0.99–6.31) 0.051 2.37 (1.08–5.23) 0.032
PCI > 6 3.57 (1.43–8.92) 0.007 4.48 (1.68–11.9) 0.003 2.87 (1.27–6.45) 0.011
Syncronous carcinomatosis 0.82 (0.34–1.96) 0.652 0.71 (0.33–1.51) 0.380
Preoperative chemotherapy 1.49 (0.57–3.88) 0.415 1.45 (0.63–3.34) 0.377
Postoperative chemotherapy 1.59 (0.37–6.88) 0.530 2.71 (0.64–11.5) 0.176
Syncronous HIPEC 0.50 (0.15–1.70) 0.270 0.49 (0.18–1.28) 0.149
Postoperative complications Clavien-Dindo > 2 0.33 (0.44–2.45) 0.279 0.48 (0.11–2.04) 0.325
Tumor grade
2 1.07 (0.14–8.30) 0.947 1.89 (0.25–14.4) 0.534
3 1.21 (0.15–9.50) 0.854 2.23 (0.29–16.9) 0.440
T4 stage 1.13 (0.46–2.76) 0.796 1.04 (0.48–2.26) 0.916
N stage
1 6.43 (1.25–33.0) 0.026 1.63 (0.49–5.33) 0.421
2 8.23 (1.86–36.4) 0.005 3.89 (1.50–10.1) 0.005 3.05 (1.78–7.88) 0.022 2.44 (1.11–5.36) 0.027
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compared to 23 (92%) incomplete CRS patients (P = 0.461).
Median OS of patients with incomplete CRS (median
follow-up 30 months, IQR 27–46) was 16 months, signifi-
cantly lower than that of patients in the CRS-HIPEC
group (Fig. 4).
Discussion
CRS-HIPEC can substantially improve survival in patients
with PC from CRC. In our study, median OS of patients
undergoing CRS-HIPEC was 60 months, an outcome simi-
lar to that reported by others [7–9, 18]. Recently, a metaa-
nalysis [19] including 3179 patients from 15 controlled
studies showed that CRS-HIPEC can significantly prolong
survival in selected CRC patients with PC with respect to
traditional treatments such as palliative surgery alone or
systemic chemotherapy (HR = 2.67, 95% CI 2.21–3.23, P <
0.00001). Additionally, authors performing a pooled ana-
lysis on outcomes from 76 studies (10,036 patients, 16 con-
trolled studies, and 61 non-controlled studies) showed that
the median OS was about 29 months in patients undergo-
ing CRS-HIPEC. Of note, only one randomized [20] con-
trolled trial was published during the 30-year period
considered in the metaanalysis. In this trial, Verwaal et al. [20]
demonstrated a significantly improved survival in patients
undergoing CRS-HIPEC and adjuvant systemic 5-fluorouracil
with leucovorin compared to those who received systemic
5-fluorouracil with leucovorin alone. The true benefit of
CRS-HIPEC in that study was difficult to interpret as the
chemotherapy schemes were outdated compared to current
ones. Recently, Cashin et al. [21] designed another random-
ized controlled trial but were forced to terminate it prema-
turely because of recruitment difficulties. However, they
published results on 48 patients (24 per arm), reporting a sig-
nificant survival benefit in patients who had CRS-HIPEC
compared to those treated with oxaliplatin-based chemother-
apy alone. PRODIGE-7 is the most recent trial comparing
CRS-HIPEC with CRS in association with systemic chemo-
therapy [22]. The authors found no significant difference
Fig. 2 Kaplan-Meier showing survival curves according to PCI (a), N status (b), and the combination of PCI and N status (c)
Fig. 3 Kaplan-Meier curves showing disease-free survival according to N status (N0 vs N1 vs N2)
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between groups in terms of OS and progression-free survival,
concluding that the addition of oxaliplatin to HIPEC did not
influence OS.
It is widely acknowledged that the completeness of cytore-
duction is one of the key factors to prolonging survival. In
our study, the group of patients undergoing CRS-HIPEC
showed an almost fourfold longer median survival than those
who had incomplete cytoreduction, a finding also confirmed
by other authors [7, 9, 23, 24]. As the probability of achieving
a complete macroscopic cytoreduction could be related to
the experience of the surgeon [10], we believe that patients
requiring CRS-HIPEC should be referred to specialized
high-volume centers. This was also recommended in the
most recent ESMO guidelines on the topic [11].
As shown in our study, PCI was a significant prognos-
tic factor in patients who underwent CRS-HIPEC. In
fact, this variable has been recognized as one of the most
important prognostic factors in patients with PC from
CRC [7, 23, 25–27]. Goéré et al. found that CRS-HIPEC
was not associated with a survival benefit in patients
with a PCI score of ≥ 17 when compared with palliative
treatment [28]. We found that N2 patients with PCI > 6
had a significantly poorer prognosis with a median sur-
vival of 18 months. Taking into account this latter finding,
which is very similar to results achieved with modern
chemotherapy, we believe that CRS-HIPEC might not be
indicated in N2 patients with PCI > 6. Larger prospective
studies are required to confirm these findings and improve
patients’ selection.
The limitations of our study are linked to its retrospect-
ive nature given that selection bias may have affected the
entire cohort. Furthermore, the lack of perioperative data
in the group of patients with incomplete CRS did not
permit a proper comparison of short-term outcomes of
surgery.
Conclusions
CRS-HIPEC can greatly improve survival in CRC patient
with PC. Complete cytoreduction (CC0) is required to
achieve the best long-term results. Patients with high PCI
(PCI > 6) and significant nodal involvement (N2) may not
benefit from the procedure.
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